Stockscreener 앱 받기
5.35
10.54%
0.51
시간 외 거래:
5.37
0.02
+0.37%
전일 마감가:
$4.84
열려 있는:
$4.82
하루 거래량:
662.21K
Relative Volume:
2.11
시가총액:
$302.09M
수익:
$2.76M
순이익/손실:
$-49.12M
주가수익비율:
-3.5667
EPS:
-1.5
순현금흐름:
$-46.21M
1주 성능:
+26.48%
1개월 성능:
+35.10%
6개월 성능:
+96.69%
1년 성능:
-3.95%
1일 변동 폭
$4.64
$5.40
1주일 범위
$4.15
$5.40
52주 변동 폭
$2.20
$6.30
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
OBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
5.35 | 273.29M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials - MSN
How currency fluctuations impact Orchestra BioMed Holdings Inc. stockDividend Hike & Low Drawdown Trading Strategies - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 2025July 2025 Snapshot & Entry and Exit Point Strategies - newser.com
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease - MSN
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Is Orchestra BioMed Holdings Inc. stock supported by strong cash flowsWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Is Orchestra BioMed Ready For Landmark Year With Trial Enrollment And Cash Strength? - RTTNews
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.2025 Volatility Report & Expert Curated Trade Setups - newser.com
Orchestra BioMed Holdings Director David P Hochman Acquires 5,000 Shares - TradingView
Chmn Hochman Buys 5,000 ($20.4K) Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity - Stock Titan
Is this a good reentry point in Orchestra BioMed Holdings Inc.Day Trade & Free Verified High Yield Trade Plans - newser.com
Research Analysts Offer Predictions for OBIO FY2025 Earnings - Defense World
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight Recommendation - MSN
Will Orchestra BioMed Holdings Inc. stock recover after recent drop2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Can Orchestra BioMed Holdings Inc. stock withstand economic slowdownJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Chmn Hochman Surrenders 6,566 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
Views of Wall Street’s Leading Experts on Orchestra BioMed Holdings Inc - Setenews
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon - MSN
Orchestra BioMed Secures FDA Breakthrough Designation - TipRanks
Orchestra BioMed Holdings, Inc. Provides Significant Business Updates - TradingView
[8-K] Orchestra BioMed Holdings, Inc. Reports Material Event | OBIO SEC FilingForm 8-K - Stock Titan
Orchestra BioMed Holdings Insiders May Regret Not Buying More, Market Cap Hits US$232m - simplywall.st
Can Orchestra BioMed Holdings Inc. stock reach $100 price target - newser.com
Barclays Maintains Orchestra BioMed Holdings (OBIO) Overweight Recommendation - Nasdaq
Barclays Lowers Price Target for OBIO While Maintaining Overweig - GuruFocus
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones - MSN
Orchestra BioMed to Deliver Major Business Update Amid Rapid Clinical Momentum - MSN
Orchestra BioMed Secures Funding And Upgrades Clinical Plans - Finimize
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - The Manila Times
Orchestra BioMed (NASDAQ: OBIO) to join Jefferies London and Piper; Dec. 3 fireside chat - Stock Titan
What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings - Yahoo Finance
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):